share_log

Elevance Health's (NYSE:ELV) Investors Will Be Pleased With Their Favorable 72% Return Over the Last Three Years

Elevance Health's (NYSE:ELV) Investors Will Be Pleased With Their Favorable 72% Return Over the Last Three Years

Elevance Health(紐約證券交易所代碼:ELV)的投資者將對過去三年72%的豐厚回報感到滿意
Simply Wall St ·  02/21 06:46

By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at attractive prices, your portfolio returns could exceed the average market return. For example, the Elevance Health, Inc. (NYSE:ELV) share price is up 66% in the last three years, clearly besting the market return of around 11% (not including dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 6.5% in the last year , including dividends .

通過購買指數基金,您可以輕鬆地大致匹配市場回報。但是,如果你以誘人的價格收購優秀的企業,你的投資組合回報率可能會超過平均市場回報。例如,Elevance Health, Inc.(紐約證券交易所代碼:ELV)的股價在過去三年中上漲了66%,顯然超過了約11%(不包括股息)的市場回報率。但是,最近的回報並不那麼令人印象深刻,該股去年的回報率僅爲6.5%,包括股息。

So let's assess the underlying fundamentals over the last 3 years and see if they've moved in lock-step with shareholder returns.

因此,讓我們評估過去3年的基本面,看看它們是否與股東回報步調一致。

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

引用巴菲特的話說:“船隻將在世界各地航行,但Flat Earth Society將蓬勃發展。市場上的價格和價值之間將繼續存在巨大差異...”通過比較每股收益(EPS)和一段時間內的股價變化,我們可以了解投資者對公司的態度是如何隨着時間的推移而變化的。

During three years of share price growth, Elevance Health achieved compound earnings per share growth of 12% per year. This EPS growth is lower than the 19% average annual increase in the share price. This indicates that the market is feeling more optimistic on the stock, after the last few years of progress. It's not unusual to see the market 're-rate' a stock, after a few years of growth.

在三年的股價增長中,Elevance Health實現了每年12%的複合每股收益增長。每股收益的增長低於股價平均年增長19%。這表明,在過去幾年的進展之後,市場對該股感到更加樂觀。在經歷了幾年的增長之後,市場 “重新評級” 股票的情況並不少見。

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

你可以在下面看到 EPS 是如何隨着時間的推移而變化的(點擊圖片發現確切的值)。

earnings-per-share-growth
NYSE:ELV Earnings Per Share Growth February 21st 2024
紐約證券交易所:ELV 每股收益增長 2024 年 2 月 21 日

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.

在買入或賣出股票之前,我們始終建議仔細研究歷史增長趨勢,可在此處查閱。

What About Dividends?

分紅呢?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, Elevance Health's TSR for the last 3 years was 72%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!

重要的是要考慮任何給定股票的股東總回報率和股價回報率。股東總回報率是一種回報計算方法,它考慮了現金分紅的價值(假設收到的任何股息都經過再投資)以及任何貼現資本籌集和分拆的計算價值。因此,對於支付豐厚股息的公司來說,股東總回報率通常遠高於股價回報率。碰巧的是,Elevance Health在過去3年的股東總回報率爲72%,超過了前面提到的股價回報率。這在很大程度上是其股息支付的結果!

A Different Perspective

不同的視角

Elevance Health shareholders gained a total return of 6.5% during the year. But that was short of the market average. If we look back over five years, the returns are even better, coming in at 12% per year for five years. It's quite possible the business continues to execute with prowess, even as the share price gains are slowing. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

Elevance Health的股東在年內獲得了6.5%的總回報。但這低於市場平均水平。如果我們回顧五年,回報率甚至更高,五年內每年爲12%。儘管股價上漲放緩,但該業務很有可能繼續保持強勁的執行力。大多數投資者花時間檢查內幕交易數據。你可以點擊這裏查看內部人士是否在買入或賣出。

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

對於那些喜歡尋找中獎投資的人來說,這份最近有內幕收購的成長型公司的免費名單可能只是門票。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論